1. Home
  2. LGND vs ICUI Comparison

LGND vs ICUI Comparison

Compare LGND & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • ICUI
  • Stock Information
  • Founded
  • LGND 1987
  • ICUI 1984
  • Country
  • LGND United States
  • ICUI United States
  • Employees
  • LGND 68
  • ICUI N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • ICUI Medical/Dental Instruments
  • Sector
  • LGND Health Care
  • ICUI Health Care
  • Exchange
  • LGND Nasdaq
  • ICUI Nasdaq
  • Market Cap
  • LGND 3.2B
  • ICUI 3.0B
  • IPO Year
  • LGND 1992
  • ICUI 1992
  • Fundamental
  • Price
  • LGND $184.44
  • ICUI $116.21
  • Analyst Decision
  • LGND Strong Buy
  • ICUI Buy
  • Analyst Count
  • LGND 8
  • ICUI 6
  • Target Price
  • LGND $144.71
  • ICUI $179.40
  • AVG Volume (30 Days)
  • LGND 139.7K
  • ICUI 216.6K
  • Earning Date
  • LGND 08-05-2025
  • ICUI 11-06-2025
  • Dividend Yield
  • LGND N/A
  • ICUI N/A
  • EPS Growth
  • LGND N/A
  • ICUI N/A
  • EPS
  • LGND N/A
  • ICUI N/A
  • Revenue
  • LGND $181,488,000.00
  • ICUI $2,372,504,000.00
  • Revenue This Year
  • LGND $18.41
  • ICUI N/A
  • Revenue Next Year
  • LGND $18.87
  • ICUI N/A
  • P/E Ratio
  • LGND N/A
  • ICUI N/A
  • Revenue Growth
  • LGND 53.40
  • ICUI 2.96
  • 52 Week Low
  • LGND $81.74
  • ICUI $107.00
  • 52 Week High
  • LGND $129.90
  • ICUI $196.26
  • Technical
  • Relative Strength Index (RSI)
  • LGND 58.00
  • ICUI 41.72
  • Support Level
  • LGND $182.87
  • ICUI $119.74
  • Resistance Level
  • LGND $194.44
  • ICUI $125.00
  • Average True Range (ATR)
  • LGND 5.35
  • ICUI 3.31
  • MACD
  • LGND -0.77
  • ICUI 0.13
  • Stochastic Oscillator
  • LGND 40.05
  • ICUI 20.95

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About ICUI ICU Medical Inc.

ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.

Share on Social Networks: